Similar articles for PMID: 24841329

Year	Number of Results
1949	1
1951	1
1953	1
1986	1
1988	1
1990	1
1993	1
1998	2
1999	1
2000	4
2001	2
2002	2
2003	9
2004	7
2005	3
2006	5
2007	13
2008	12
2009	15
2010	15
2011	24
2012	18
2013	20
2014	41
2015	51
2016	30
2017	32
2018	34
2019	38
2020	24
2021	28
2022	28
2023	3
2024	0

1

Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.

Clay E, Khemiri A, Zah V, Aballéa S, Ruby J, Asche CV. Clay E, et al. J Med Econ. 2014 Sep;17(9):626-36. doi: 10.3111/13696998.2014.925463. Epub 2014 Jun 6. J Med Econ. 2014. PMID: 24841329 Free article.

2

Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.

Khemiri A, Kharitonova E, Zah V, Ruby J, Toumi M. Khemiri A, et al. Postgrad Med. 2014 Sep;126(5):113-20. doi: 10.3810/pgm.2014.09.2805. Postgrad Med. 2014. PMID: 25295655

3

Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.

Kaur AD, McQueen A, Jan S. Kaur AD, et al. J Manag Care Pharm. 2008 Mar;14(2):186-94. doi: 10.18553/jmcp.2008.14.2.186. J Manag Care Pharm. 2008. PMID: 18331120 Free PMC article.

4

Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States.

Asche CV, Clay E, Kharitonova E, Zah V, Ruby J, Aballéa S. Asche CV, et al. J Med Econ. 2015;18(8):600-11. doi: 10.3111/13696998.2015.1036760. Epub 2015 May 20. J Med Econ. 2015. PMID: 25851505 Free article.

5

Cost and utilization outcomes of opioid-dependence treatments.

Baser O, Chalk M, Fiellin DA, Gastfriend DR. Baser O, et al. Am J Manag Care. 2011 Jun;17 Suppl 8:S235-48. Am J Manag Care. 2011. PMID: 21761950

6

Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.

Gunderson EW, Hjelmström P, Sumner M; 006 Study Investigators. Gunderson EW, et al. Clin Ther. 2015 Oct 1;37(10):2244-55. doi: 10.1016/j.clinthera.2015.08.025. Epub 2015 Sep 26. Clin Ther. 2015. PMID: 26412801 Free article. Clinical Trial.

7

The diversion and injection of a buprenorphine-naloxone soluble film formulation.

Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, White N, Degenhardt L. Larance B, et al. Drug Alcohol Depend. 2014 Mar 1;136:21-7. doi: 10.1016/j.drugalcdep.2013.12.005. Epub 2014 Jan 8. Drug Alcohol Depend. 2014. PMID: 24461476

8

Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.

Webster L, Hjelmström P, Sumner M, Gunderson EW. Webster L, et al. J Addict Dis. 2016 Oct-Dec;35(4):325-338. doi: 10.1080/10550887.2016.1195608. Epub 2016 Jun 7. J Addict Dis. 2016. PMID: 27267785 Clinical Trial.

9

Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update.

Soyka M. Soyka M. Expert Opin Drug Deliv. 2015 Feb;12(2):339-47. doi: 10.1517/17425247.2014.953479. Epub 2014 Aug 25. Expert Opin Drug Deliv. 2015. PMID: 25156759 Review.

10

Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.

Soyka M. Soyka M. Expert Opin Drug Deliv. 2012 Nov;9(11):1409-17. doi: 10.1517/17425247.2012.729574. Epub 2012 Sep 26. Expert Opin Drug Deliv. 2012. PMID: 23013384 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

413 results

Results by year